Vaccine combination lowers rate of HIV infection

The U.S. Army Surgeon General released data from the Phase III RV144 trial showing that ALVAC HIV vaccine from sanofi-aventis Group (Euronext:SAN; NYSE:SNY) boosted by the AIDSVAX B/E gp120 vaccine lowered the rate of HIV infection by 31.1% vs. placebo at three years (p=0.04). The double-blind, Thai trial enrolled 16,402 adult volunteers. ALVAC is a recombinant canarypox vector HIV encoding portions of the env, gag and pol proteins of HIV-1. ...